What are the treatment options for metastatic Prostate Cancer

Treatment Options for Metastatic Prostate Cancer

Metastatic prostate cancer means the cancer has spread beyond the prostate to other parts of the body—commonly to bones, lymph nodes, or internal organs like the liver or lungs. The good news is that several effective treatment approaches exist, and doctors now use combinations of therapies rather than single treatments alone.

How Doctors Approach Metastatic Prostate Cancer

According to the NCCN Guidelines for Advanced-Stage Prostate Cancer, treatment decisions depend on two key factors:

1. Whether the cancer is hormone-sensitive (still responding to hormone therapy) or hormone-resistant (continuing to grow despite low testosterone)
2. The cancer burden (how much cancer is present and where it's located)

---

HORMONE-SENSITIVE METASTATIC PROSTATE CANCER

This is when your cancer still responds to hormone-lowering therapy. Treatment has changed significantly in recent years—it's no longer standard to use hormone therapy alone.

Main Treatment: Androgen Deprivation Therapy (ADT)

ADT reduces testosterone (the hormone that fuels prostate cancer) to near-zero levels, called "castration level." This can be done through:

• Injected medications (LHRH agonists or LHRH antagonists)
• Surgical removal of the testicles (less common today)

Standard Approach: Combination Therapy

According to NCCN Guidelines, the preferred treatment now combines ADT with additional therapies:

Doublet Therapy (ADT + One Additional Drug):

• Second hormone therapies (preferred options):

  • Abiraterone (Zytiga)
  • Enzalutamide (Xtandi)
  • Apalutamide (ARN-509)

  Research shows patients on ADT plus these drugs live longer than those on ADT alone.

Triplet Therapy (ADT + Two Additional Drugs):

• ADT + chemotherapy (docetaxel) + a second hormone therapy (abiraterone or darolutamide)
• Reserved for patients with high-volume disease (multiple bone metastases or cancer in internal organs) who can physically tolerate the combination

---

HORMONE-RESISTANT METASTATIC PROSTATE CANCER

This occurs when cancer continues growing despite hormone therapy. Multiple options exist depending on your prior treatments.

Second Hormone Therapy

If you haven't had chemotherapy yet, doctors may try:

• Abiraterone (Zytiga)
• Enzalutamide (Xtandi)
• Other options: nilutamide, flutamide, bicalutamide, or corticosteroids

Chemotherapy

Docetaxel is the preferred chemotherapy option. If that stops working, alternatives include:

• Cabazitaxel
• Carboplatin combined with other drugs
• Cisplatin or mitoxantrone (in specific cases)

Immunotherapy

Immunotherapy helps your immune system fight cancer cells:

• Sipuleucel-T (Provenge): Used for patients with few or no symptoms and less cancer burden. Works best when the immune system is still strong.

• Pembrolizumab (Keytruda): Used for patients whose cancer has specific genetic changes (mismatch repair deficiency or high microsatellite instability). Only recommended after chemotherapy and second hormone therapy have been tried.

Biomarker-Targeted Therapies (PARP Inhibitors)

If genetic testing shows you have BRCA1 or BRCA2 mutations (genes that repair DNA), you may be eligible for:

• Olaparib (Lynparza) - can be used earlier in treatment or after other therapies fail
• Rucaparib (Rubraca) - used after hormone therapy and chemotherapy
• Niraparib + abiraterone (Akeega) - newer combination option
• Talazoparib + enzalutamide (Talzenna) - another newer combination

These drugs work by blocking PARP, an enzyme that helps cancer cells repair DNA damage. Without this repair mechanism, cancer cells die.

Radiopharmaceuticals

These are radioactive drugs that target cancer cells:

• Lutetium-177 (Pluvicto): A radioactive particle that attaches to PSMA (a protein on prostate cancer cells). Used after hormone therapy and chemotherapy. First, you'll have a PSMA-PET scan to confirm it will work for you. According to expert Dr. [removed] Sartor, about one-third of patients have excellent responses, one-third have modest responses, and one-third don't respond well.

• Radium-223 (Xofigo): Used when cancer has spread mainly to bones but NOT to internal organs. Must be combined with ADT.

---

EMERGING AND INVESTIGATIONAL APPROACHES

According to recent expert webinars, several newer strategies are being researched:

• Bipolar Androgen Therapy (BAT): Cycling testosterone levels up and down. About two-thirds of patients see benefit (either disease stabilization or improvement).

• T-cell bispecifics: These are immunotherapy drugs designed to bring immune cells directly to cancer cells. Expected to become a backbone of future prostate cancer treatment.

• Combination approaches: Combining radiopharmaceuticals with immunotherapy or other targeted drugs.

• [ID removed] vaccines: Personalized vaccines targeting your specific tumor mutations.

---

SUPPORTIVE CARE

Regardless of which treatment you receive, supportive care is important:

• Bone-targeted therapy: Denosumab or zoledronic acid to prevent fractures
• Palliative radiation: Direct radiation to painful bone tumors
• Calcium and vitamin D supplements: To support bone health

---

IMPORTANT QUESTIONS TO ASK YOUR DOCTOR

1. What is my cancer burden? (How much cancer do I have and where is it located?)
2. Should I have genetic testing? (To check for BRCA mutations or other actionable mutations)
3. What combination therapy do you recommend for me, and why?
4. What are the side effects of each option, and how will we manage them?
5. Are there clinical trials I should consider?
6. How will we monitor whether treatment is working? (PSA tests, imaging, etc.)
7. What happens if this treatment stops working? (What's the next step?)

---

Key Takeaway

Treatment for metastatic prostate cancer has evolved dramatically. Rather than a single therapy, doctors now use treatment intensification—combining multiple drugs to improve survival and quality of life. Your specific treatment plan will depend on your cancer's characteristics, your overall health, and your personal goals.

According to the NCCN Guidelines, many patients with advanced prostate cancer eventually receive two, three, or more different therapies over time. This is normal and expected as cancer may develop resistance to treatments.

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.